Enliven Therapeutics reports phase 1 trial results for leukemia drug

June 11, 2026 8:01 AM

Enliven Therapeutics Inc. (NASDAQ: ELVN) reported updated results from its Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found